Task Optimizing the combination of intranasal scopolamine and sensory augmentation to mitigate G-transition induced motion sickness and enhance sensorimotor performance (Wood)
Last Published:  07/29/22 01:33:24 PM (Central)
Short Title: INSCOP and Sensory Augmentation (Wood)
Responsible HRP Element: Human Health Countermeasures
Collaborating Org(s):
Funding Status: Active - Currently funded and in progress
Procurement Mechanism(s):
Evaluate combining intranasal scopolamine and sensory augmentation as an integrated countermeasure intended to mitigate motion sickness and enhance crew performance.

Compare motion sickness symptom severity and recovery for intranasal scopolamine (0.4 mg) and placebo control that subjects self-administer during the simulated capsule wave motion following symptom onset.

Characterize the incidence of early inflight and early post-flight motion sickness and other neurovestibular symptoms, evaluate the efficacy of current motion sickness countermeasures (using both intranasal scopolamine “active” and other “control” participants), and summarize recommendations from crewmembers on what activities they would recommend doing (or avoiding) to improve inflight or postflight recovery.